drugset / Trial / NCT07458659
Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Phase 0
Not yet recruiting
3 enrolled
Chulalongkorn University
King Chulalongkorn Memorial Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
A Phase 1b clinical trial to evaluate the safety and efficacy of BCMA-targeted CAR T-cell therapy in Thai patients with relapsed or refractory multiple myeloma.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2028-06-01
- Completion
- 2029-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Chimeric Antigen Receptor T Cells (CAR-T) | Cell therapy | 5e+06 cells/kg | Intravenous |